TCT 2019 | IVUS-XPL: 5-Year Follow-up for Angiography-vs. IVUS-Guided Angioplasty

Courtesy of SBHCI.

The aim of this work, which was presented during the TCT 2019 Scientific Session and simultaneously published in JACC Intv, was to prove the benefit of intravascular ultrasound (IVUS) in angioplasty.

Highlights TCT 2019

The IVUS-XPL trial randomized 1400 patients with long coronary lesions (≥28 mm) to IVUS-guided angioplasty (n = 700) vs. angiography-guided angioplasty (n = 700). All procedures were conducted with an everolimus-eluting stent. Follow-up on patients was 5 years.

The primary endpoint was a composite of death, target-vessel-related myocardial infarction, and ischemia-driven revascularization.

About 1183 patients (85%) completed the 5-year follow-up. The composite primary endpoint occurred in 5.6% of patients who underwent IVUS-guided angioplasty vs. 10.7% of patients who underwent angiography-guided angioplasty (hazard ratio [HR]: = 0.5; p = 0.001). The difference was basically driven by lower target-vessel revascularization (4.8% vs. 8.4%; p = 0.007).

Conclusion

Comparing IVUS-guided vs. angiography-guided angioplasty with a drug-eluting stent, the former was associated with significantly lower rates of major cardiac events at 5 years.

Courtesy of SBHCI.

Link to the SBHCI publication HERE

ivus-xpl

ivus-jacc-tct2019

Original Title: IVUS-XPL: 5-Year Outcomes From a Randomized Trial of Intravascular Ultrasound-Guided vs. Angiography-Guided PCI of Long Coronary Lesions.

Author of the original title: Myeong-Ki Hong.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...